Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rashmi K Murthy

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Oncology (Williston Park, N.Y.)|February 5, 2010
Bone biology and the role of the RANK ligand pathwayRashmi K Murthy, P K Morrow, Richard L Theriault
Journal of the National Comprehensive Cancer Network : JNCCN|May 13, 2018
Genetic Counseling Referral Rates in Long-Term Survivors of Triple-Negative Breast CancerCarlos H Barcenas, Maryam N Shafaee, Arup K Sinha, et al.
Breast Cancer Research and Treatment|April 13, 2019
Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1)Luis Baez-Vallecillo, Akshara S Raghavendra, Kenneth R Hess, et al.
JCO Clinical Cancer Informatics|February 17, 2022
Reply to A. Pfob and C. Sidey-GibbonsCarlos H Barcenas, Juhee Song, Rashmi K Murthy, et al.
JCO Clinical Cancer Informatics|August 5, 2021
Prognostic Model for De Novo and Recurrent Metastatic Breast CancerCarlos H Barcenas, Juhee Song, Rashmi K Murthy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 6, 2017
Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2<sup>+</sup>-Advanced Solid Tumors, with an Expansion Cohort in HER2<sup>+</sup> Metastatic Breast Cancer (MBC)Stacy L Moulder, Virginia F Borges, Tara Baetz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2018
Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric CancerFunda Meric-Bernstam, Amber M Johnson, Ecaterina E Ileana Dumbrava, et al.
Breast Cancer Research : BCR|December 31, 2014
Outcomes of children exposed in utero to chemotherapy for breast cancerRashmi K Murthy, Richard L Theriault, Chad M Barnett, et al.
Cancer|December 15, 2023
Survival outcomes of patients with HER2/neu-positive breast cancer with germline BRCA mutationsFatma Nihan Akkoc Mustafayev, Mihir Amitabh Shukla, Amanda Lanier, et al.
NPJ Breast Cancer|March 29, 2020
Incorporation of clinical and biological factors improves prognostication and reflects contemporary clinical practiceRashmi K Murthy, Juhee Song, Akshara S Raghavendra, et al.
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Oncology (Williston Park, N.Y.)|February 5, 2010
Bone biology and the role of the RANK ligand pathwayRashmi K Murthy, P K Morrow, Richard L Theriault
Journal of the National Comprehensive Cancer Network : JNCCN|May 13, 2018
Genetic Counseling Referral Rates in Long-Term Survivors of Triple-Negative Breast CancerCarlos H Barcenas, Maryam N Shafaee, Arup K Sinha, et al.
Breast Cancer Research and Treatment|April 13, 2019
Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1)Luis Baez-Vallecillo, Akshara S Raghavendra, Kenneth R Hess, et al.
JCO Clinical Cancer Informatics|February 17, 2022
Reply to A. Pfob and C. Sidey-GibbonsCarlos H Barcenas, Juhee Song, Rashmi K Murthy, et al.
JCO Clinical Cancer Informatics|August 5, 2021
Prognostic Model for De Novo and Recurrent Metastatic Breast CancerCarlos H Barcenas, Juhee Song, Rashmi K Murthy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 6, 2017
Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2<sup>+</sup>-Advanced Solid Tumors, with an Expansion Cohort in HER2<sup>+</sup> Metastatic Breast Cancer (MBC)Stacy L Moulder, Virginia F Borges, Tara Baetz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2018
Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric CancerFunda Meric-Bernstam, Amber M Johnson, Ecaterina E Ileana Dumbrava, et al.
Breast Cancer Research : BCR|December 31, 2014
Outcomes of children exposed in utero to chemotherapy for breast cancerRashmi K Murthy, Richard L Theriault, Chad M Barnett, et al.
Cancer|December 15, 2023
Survival outcomes of patients with HER2/neu-positive breast cancer with germline BRCA mutationsFatma Nihan Akkoc Mustafayev, Mihir Amitabh Shukla, Amanda Lanier, et al.
NPJ Breast Cancer|March 29, 2020
Incorporation of clinical and biological factors improves prognostication and reflects contemporary clinical practiceRashmi K Murthy, Juhee Song, Akshara S Raghavendra, et al.
Pageof 5